JUNS JUNS
Company Profile ↓Company Overview
JUNS (JUNS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -94.87% |
| 6 Months: | -86.47% |
| 3 Months: | -78.67% |
| 1 Month: | -64.35% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)23.46 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 95.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 23 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 18.65K |
| Gross Profit | - | - | - | - | - | - | - | - | - | 14.29K |
| Operating Income | - | - | -1.44M | -570.70K | -557.08K | -493.55K | -1.54M | -2.26M | -2.30M | -1.96M |
| Net Income | -1.75M | -832.61K | -1.77M | -634.10K | 313.12K | -591.02K | -1.53M | -2.25M | -2.29M | -2.06M |
| Diluted EPS | - | - | -0.07 | -0.02 | 0.01 | -0.02 | -0.05 | -0.07 | -0.07 | -0.06 |
| R&D Expense | - | - | 239.46K | 98.67K | 101.08K | 91.91K | 466.75K | 759.45K | 816.70K | 411.05K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | - | 0 | 21.80K |
| Gross Profit | - | - | 17.57K |
| Operating Income | -3.87M | -3.09M | -8.91M |
| Net Income | -4.78M | -2.44M | -8.64M |
| Diluted EPS | -0.18 | -0.08 | -0.25 |
| R&D Expense | 954.79K | 492.66K | 2.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 148.59K | 6.20M | 5.56M |
| Total Equity | -7.14M | -5.80M | 4.17M | -1.83M |
| Total Liabilities | - | 5.95M | 2.03M | 7.40M |
| Current Liabilities | - | 5.77M | 2.01M | 7.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -480.95K | -3.91M | -5.41M |
| Financing Cash Flow | 445.00K | 7.65M | 5.43M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | 80.6% |
| Operating Margin % | - | - | -40,873.2% |
| Net Margin % | - | - | -39,662.8% |
| ROE % | 82.5% | -58.5% | 471.9% |
| ROCE % | 68.8% | -73.7% | 486.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JUNS
Jupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026 - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQZ21hbjFXdHQzRmU1RG5aYjJZOGJUQWV1NFpQLS1wQjJNUHlyaTZxX2xQX0phUjFvdFpPZDNBQ3Zwdjh2eG9PUHdzWnlHU0JmbWktRUstZmxzSnVzUksyZWFZN2JsVDRrRE9ac0JoeGJzbndPdlBZanoyVXNjRTlmRERZWnMyYXJTQTV2d1…
Jupiter Neurosciences (JUNS) Stock Forecast & Analyst Ratings - Moomoo
<a href="https://news.google.com/rss/articles/CBMi0AJBVV95cUxOQlAtX3FwM0FPRWs4eG55YUJKWkZpRjU1T3I1OVlZdnFULWNHMWRIUjdKSlptaGJLNUNtWlZVcmtLWTM2c0d3ZVdqbFdZdFFOZUxyR2c5d19FRWUydGVHU0lOQzVDQjJnQUhCRUg1TFhzZGNHZDVUbVVNNXFnc21wVElpREpyZFdPZ2tsR3…
Jupiter Neurosciences, Inc. Announces Reverse Stock Split - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOZ3YxS1A2WFV0WDJNNEd3dVRfTzFrajl1Qmp5Mm1hZ2l4bElLLVJzRnJRTGVWUnFYdlM0SGJob1BlTnJmdXYtTFgzX0dGd0xwb0d2N3o0bG9LUEQ3LUZsVHEteGxFQkpsVHJuVDZSaEc3Y09FUTgwTVI2NXB5b0VDenJDaHJycEZOZkxlYm…
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNWFJ3Ym5jd1gzREEzZS01UVlmYWg5ODY3b2pHNGFiR0xUMGoyQk1SWFczMUhvdDVPQ2xiUWNielRheEU3S044bjdaT0didmhmWE9FVFBsU3Z3Z1lvUzY2ZkZmbklvbm5IYlVJT0J6TnQ4aG96QXduRmw0ejR0ODE4YWkyYzNQQXk4U213cH…
Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPazFZaDR4RG1Zb0EwYVRxTHJoUmNsQmVkQTk2cl9yYWZqNVcyOTBpYXFESkZ5b3IzXy1WbElmNXgtSVBKd1o5dTM3Y1VfSXhfSGJrQllmUzRNLVVmUWFGZW0zN3pLYnhoamt4Q2pLRF9sMUlhOXJjZ1lsX0JuS2F3bzE1T01nU0U1QXAxYz…
Jupiter Neurosciences, Inc. Revenue Breakdown – NASDAQ:JUNS - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBNUXlzYUV2Mm50VFJ3eW1aM2hHSDl0ZDJnWXRTQ2M3YjJYTHJIR19tV1k3dm1QRGlVTjNKMlplcU9VM1JBTEgydkdYR2t4QldIa3NzWjZXaU5lQWVDeHFlTGFHQUpBUG9jQjJPLUFLOEtuVUlzY0dj?oc=5" target="_blank">Jupiter…
JUNS — Frequently Asked Questions
What is the current share price of JUNS?
As of 2026-08-05 17:25 PDT, JUNS trades at $0.08 on NASDAQ/NYSE. Its 52-week range is $0.08 to $1.80.
What is the P/E ratio of JUNS?
JUNS trades at a trailing price-to-earnings (P/E) ratio of -0.32.
Is JUNS a good stock to buy?
This page provides a data-driven analysis of JUNS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.